Inhibition of nociceptive responses after systemic administration of amidated kyotorphin

British Journal of Pharmacology

Volumn 163, Issue 5, 2011, Pages 964-973

  Ribeiro, M M B ^a,b   Pinto, A ^b,c   Pinto, M ^b,c   Heras, M ^d   Martins, I ^b,c   Correia, A ^a   Bardaji, E ^d   Tavares, I ^b,c   Castanho, M ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF GIRONA   (Spain)

Author keywords

analgesic; blood brain barrier; kyotorphin; neuropeptide; pain

Indexed keywords

KYOTORPHIN; KYOTORPHIN AMIDE; MORPHINE; NALOXONE; OPIATE RECEPTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AMIDATION; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CHRONIC PAIN; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSAGE FORM COMPARISON; DRUG INHIBITION; DRUG PENETRATION; HOT PLATE TEST; HUMAN; HUMAN CELL; HYPOTENSION; LIPOPHILICITY; LIVER TOXICITY; MALE; MOTOR DYSFUNCTION; NEPHROTOXICITY; NEUROPATHIC PAIN; NONHUMAN; PAIN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SPINAL CORD NERVE CELL; SPLEEN DISEASE; TAIL FLICK TEST;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANALGESICS; ANIMALS; BLOOD-BRAIN BARRIER; CHRONIC DISEASE; DIPEPTIDES; DISEASE MODELS, ANIMAL; ENDORPHINS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SPINAL; MALE; PAIN; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, OPIOID;

EID: 79955630518     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01290.x     Document Type: Article

References (32)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC). 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Arima T, Kitamura Y, Nishiya T, Taniguchi T, Takagi H, Nomura Y, (1997). Effects of kyotorphin (L-tyrosyl-L-arginine) ON[3H]NG-nitro-L-arginine binding to neuronal nitric oxide synthase in rat brain. Neurochem Int 30: 605-611. (Pubitemid 27187231)
3. Butler SH, Godefroy F, Besson JM, Weil-Fugazza J, (1992). A limited arthritic model for chronic pain studies in the rat. Pain 48: 73-81.
4. Chen P, Bodor N, Wu WM, Prokai L, (1998). Strategies to target kyotorphin analogues to the brain. J Med Chem 41: 3773-3781. (Pubitemid 28447304)
5. Coggeshall RE, (2005). Fos, nociception and the dorsal horn. Prog Neurobiol 77: 299-352. (Pubitemid 41815592)
6. D'Amour F, Smith D, (1941). A method for determining loss of pain sensation. J Pharmacol Exp Ter 72: 74-79.
7. Decosterd I, Woolf CJ, (2000). Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87: 149-158. (Pubitemid 30621447)
8. Dubuisson D, Dennis SG, (1977). The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4: 161-174. (Pubitemid 8234766)
9. Haseto S, Ouchi H, Isoda T, Mizuma T, Hayashi M, Awazu S, (1994). Transport of low and high molecular peptides across rabbit Peyer's patches. Pharm Res 11: 361-364. (Pubitemid 24117352)
10. Huidobro-Toro JP, Canessa M, Fischer S, (1976). Interaction of morphine with cholesterol monolayers. Biochim Biophys Acta 436: 237-241.
11. Kissin I, (2010). The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg 110: 780-789.
12. Kolaeva SG, Semenova TP, Santalova IM, Moshkov DA, Anoshkina IA, Golozubova V, (2000). Effects of L-thyrosyl-L-arginine (kyotorphin) on the behavior of rats and goldfish. Peptides 21: 1331-1336.
13. Lopes SC, Soares CM, Baptista AM, Goormaghtigh E, Cabral BJ, Castanho MA, (2006). Conformational and orientational guidance of the analgesic dipeptide kyotorphin induced by lipidic membranes: putative correlation toward receptor docking. J Phys Chem B Condens Matter Mater Surf Interfaces Biophys 110: 3385-3394.
14. Machuqueiro M, Baptista AM, (2007). The pH-dependent conformational states of kyotorphin: a constant-pH molecular dynamics study. Biophys J 92: 1836-1845. (Pubitemid 46495250)
15. Martins I, Costa-Araujo S, Fadel J, Wilson SP, Lima D, Tavares I, (2010). Reversal of neuropathic pain by HSV-1-mediated decrease of noradrenaline in a pain facilitatory area of the brain. Pain 151: 137-145.
16. Melzack R, (2008). The future of pain. Nat Rev Drug Discov 7: 629.
17. Ottoni EB, (2000). EthoLog 2.2: a tool for the transcription and timing of behavior observation sessions. Behav Res Methods Instrum Comput 32: 446-449.
18. Pan B, Castro-Lopes JM, Coimbra A, (1997). Chemical sensory deafferentation abolishes hypothalamic pituitary activation induced by noxious stimulation or electroacupuncture but only decreases that caused by immobilization stress. A c-fos study. Neuroscience 78: 1059-1068. (Pubitemid 27223711)
19. Patti CL, Frussa-Filho R, Silva RH, Carvalho RC, Kameda SR, Takatsu-Coleman AL, et al,. (2005). Behavioral characterization of morphine effects on motor activity in mice. Pharmacol Biochem Behav 81: 923-927. (Pubitemid 41187829)
20. Pinto M, Lima D, Castro-Lopes J, Tavares I, (2003). Noxious-evoked c-fos expression in brainstem neurons immunoreactive for GABAB, mu-opioid and NK-1 receptors. Eur J Neurosci 17: 1393-1402. (Pubitemid 36560838)
21. Rackham A, Wood PL, Hudgin RL, (1982). Kyotorphin (tyrosine-arginine): further evidence for indirect opiate receptor activation. Life Sci 30: 1337-1342. (Pubitemid 12073653)
22. Rougeot C, Robert F, Menz L, Bisson JF, Messaoudi M, (2010). Systemically active human opiorphin is a potent yet non-addictive analgesic without drug tolerance effects. J Physiol Pharmacol 61: 483-490.
23. Shiomi H, Ueda H, Takagi H, (1981). Isolation and identification of an analgesic opioid dipeptide kyotorphin (Tyr-Arg) from bovine brain. Neuropharmacology 20: 633-638. (Pubitemid 11126352)
24. Takagi H, Shiomi H, Ueda H, Amano H, (1979a). Morphine-like analgesia by a new dipeptide, L-tyrosyl-L-arginine (Kyotorphin) and its analogue. Eur J Pharmacol 55: 109-111. (Pubitemid 9220149)
25. Takagi H, Shiomi H, Ueda H, Amano H, (1979b). A novel analgesic dipeptide from bovine brain is a possible Met-enkephalin releaser. Nature 282: 410-412. (Pubitemid 10206420)
26. Tavares I, Almeida A, Albino-Teixeira A, Lima D, (1997). Lesions of the caudal ventrolateral medulla block the hypertension-induced inhibition of noxious-evoked c-fos expression in the rat spinal cord. Eur J Pain 1: 149-160. (Pubitemid 127673849)
27. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K, (1992). The formalin test: an evaluation of the method. Pain 51: 5-17.
28. Ueda H, Yoshihara Y, Misawa H, Fukushima N, Katada T, Ui M, et al,. (1989). The kyotorphin (tyrosine-arginine) receptor and a selective reconstitution with purified Gi, measured with GTPase and phospholipase C assays. J Biol Chem 264: 3732-3741. (Pubitemid 19072250)
29. Ueda H, Yoshihara Y, Takagi H, (1986). A putative met-enkephalin releaser, kyotorphin enhances intracellular Ca2+ in the synaptosomes. Biochem Biophys Res Commun 137: 897-902. (Pubitemid 16044472)
30. Woodcock J, Witter J, Dionne RA, (2007). Stimulating the development of mechanism-based, individualized pain therapies. Nat Rev Drug Discov 6: 703-710. (Pubitemid 47338179)
31. Xu W, Yoon SI, Huang P, Wang YL, Chen CG, Chong PLG, et al,. (2006). Localization of the kappa opioid receptor in lipid rafts. J Pharmacol Exp Ther 317: 1295-1306. (Pubitemid 43764136)
32. Zimmermann M, (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110. (Pubitemid 13058546)